Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to ...

Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental

Related Keywords

Luxembourg ,Esch Sur Alzette ,Jens Schwamborn ,Jenniferk Zimmons ,Robert Fremeau ,Vyant Bio ,Jay Roberts ,Linkedin ,Company Nasdaq ,Company Nadsaq ,Twitter ,Organotherapeutics Co ,University Of Luxembourg ,Exchange Commission ,Cancer Genetics Inc ,Stemonix Inc ,Vyant Bio Inc ,Zimmons International Communications Inc ,Luxembourg Centre For Systems Biomedicine ,Cherry Hill ,Chief Scientific Officer ,Rett Syndrome ,Luxembourg Centre ,Systems Biomedicine ,Looking Statements ,Private Securities Litigation Reform Act ,Cancer Genetics ,International Communications , ,